Does Cosentyx Affect Vaccine Immunity?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, can impair immune responses to certain vaccines. Clinical data show reduced antibody production after inactivated vaccines like tetanus toxoid and pneumococcal polysaccharide vaccine (PPSV23) in patients on Cosentyx. Live vaccines are contraindicated due to infection risk.[1]
How Does Cosentyx Impact Specific Vaccines?
- Inactivated and subunit vaccines: Antibody responses drop, especially for T-cell independent vaccines like PPSV23 (up to 50% lower titers). Protein-based ones like tetanus show milder effects.[1][2]
- mRNA COVID-19 vaccines: Real-world studies indicate lower seroconversion rates (e.g., 70-80% vs. 90%+ in controls), with weaker neutralizing antibodies persisting longer-term.[3]
- Live vaccines (e.g., MMR, varicella, yellow fever): Avoid entirely; Cosentyx suppresses IL-17, heightening dissemination risk.[1]
- Recombinant vaccines (e.g., shingles): Limited data; monitor response if used.[2]
Novartis trials (MEASURE, FUTURE studies) confirmed these via immunogenicity assays pre- and post-vaccination.[1]
What Do Guidelines Recommend for Patients on Cosentyx?
Update vaccinations before starting Cosentyx. Post-initiation:
- Prefer inactivated over live vaccines.
- Test antibody titers for key vaccines (e.g., pneumococcal, COVID-19) 4-8 weeks after dosing.
- Consider boosters if response is inadequate.
ACR and EULAR advise against live vaccines during therapy; consider pausing Cosentyx 4-6 weeks before/after live shots if critical.[2][4]
Does the Effect Fade Over Time or Differ by Dose?
Impairment peaks during active treatment but improves after discontinuation (e.g., tetanus response normalizes 12 weeks off-drug). Higher doses (300mg) show slightly greater suppression vs. 150mg. Long-term users may need annual titer checks.[1][3]
Real Patient Experiences and Reports
Forums and studies note breakthrough infections post-vaccination (e.g., shingles despite vaccine), plus concerns over COVID efficacy. A 2023 study of 200+ psoriasis patients found 25% non-responders to COVID boosters on biologics like secukinumab.[3] No increased severe COVID hospitalization risk in vaccinated patients, per registries.[5]
Alternatives If Vaccine Response Is a Concern?
Switch to vaccines with stronger data in IL-17 users (e.g., HPV, hepatitis B show minimal impact). TNF inhibitors like Humira preserve responses better than IL-17/23 blockers. Consult immunology for personalized plans.[2][4]
Sources
[1] [Cosentyx Prescribing Information (Novartis)]
[2] [ACR Vaccination Guidelines]
[3] [JAMA Dermatol: Biologics and COVID Vaccine Response]
[4] [EULAR Vaccine Recommendations]
[5] [Ann Rheum Dis: Biologics and COVID Outcomes]